Antibody-drug conjugates in prostate cancer: current landscape and future directions
Antibody-drug conjugates (ADCs) have emerged as a promising therapeutic option, combining the specificity of monoclonal antibodies with the potency of cytotoxic payloads. While initially developed for hematologic and select solid malignancies, advances in antigen discovery, linker chemistry, and pay...
Sparad:
| Huvudupphov: | , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
SAGE Publishing
2026-03-01
|
| Serie: | Therapeutic Advances in Medical Oncology |
| Länkar: | https://doi.org/10.1177/17588359261424672 |
| Taggar: |
Inga taggar, Lägg till första taggen!
|